VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
UNMA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
UNMAUnum Group 6.250% JR NT58
$21.36$4.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksUNMAFinancials

Unum Group 6.250% JR NT58 (UNMA) Financials

30Y historyFree accessUpdated daily

Core underwriting profitability remains susceptible to episodic volatility, as evidenced by the combined ratio fluctuating from a low of 72.3% in 2024Q3 to 91.0% in 2026Q1.

UNMA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue13.3B13.05B12.79B12.31B11.88B11.84B13.15B11.99B11.6B11.29B11.05B10.73B10.52B10.37B10.52B10.28B10.19B10.09B9.98B10.52B10.54B10.44B10.46B9.82B9.08B9B9.07B9.33B8.52B7.68B4.07B
Revenue Growth %4.84%2.07%3.91%3.65%0.32%-9.96%9.63%3.4%2.76%2.18%2.94%1.96%1.5%-1.4%2.31%0.83%1.01%1.09%-5.11%-0.15%0.94%-0.26%6.58%8.08%0.91%-0.76%-2.77%9.51%10.97%88.55%-1.24%
Medical Costs & Claims8.79B8.07B8.05B8.28B7.95B8.52B10.06B8.57B9.03B8.02B7.87B7.69B8.16B7.46B7.55B8.01B7.16B6.89B8.07B8.39B7.63B8.07B8.24B8.99B7.14B6.73B6.92B8.07B6.53B5.39B2.05B
Medical Cost Ratio %66.11%61.78%62.91%67.24%66.91%71.98%76.52%71.46%77.82%71.02%71.24%71.68%77.56%71.92%71.81%77.95%70.25%68.23%80.85%79.71%72.39%77.28%78.76%91.59%78.65%74.73%76.29%86.52%76.66%70.25%50.3%
Gross Profit4.51B4.99B4.74B4.03B3.93B3.32B3.09B3.42B2.57B3.27B3.18B3.04B2.36B2.91B2.96B2.27B3.03B3.21B1.91B2.13B2.91B2.37B2.22B826M1.94B2.27B2.15B1.26B1.99B2.28B2.02B
Gross Margin %33.89%38.22%37.09%32.76%33.09%28.02%23.48%28.54%22.18%28.98%28.76%28.32%22.44%28.08%28.19%22.05%29.75%31.77%19.15%20.29%27.61%22.72%21.24%8.41%21.35%25.27%23.71%13.48%23.34%29.75%49.7%
Gross Profit Growth %-5.16%17.65%2.61%18.46%7.47%-9.8%33.05%-21.37%2.95%4.53%28.71%-18.88%-1.8%30.82%-25.28%-5.39%67.69%-10.43%-26.62%22.67%6.68%169.07%-57.41%-14.74%5.76%70.98%-36.75%-12.92%12.86%-33.1%
Operating Expenses3.52B4.06B2.49B2.39B2.18B2.06B2.12B2.04B1.94B1.87B1.83B1.8B1.82B1.69B1.72B1.93B1.71B1.91B1.09B1.14B2.44B1.66B2.48B1.28B1.36B1.52B1.33B1.42B1.07B801.1M-995.9M
OpEx / Revenue %26.43%31.07%19.49%19.44%18.36%17.37%16.15%17.01%16.76%16.54%16.56%16.79%17.29%16.31%16.31%18.81%16.81%18.96%10.9%10.81%23.19%15.92%23.72%13.02%15.03%16.89%14.66%15.26%12.54%10.43%-24.46%
Depreciation & Amortization93M123M116.1M108.8M110.5M119.8M113.6M110.1M101.4M103.4M101.7M99.5M87.9M84.8M84.3M81.1M75.4M74.5M68.8M66.2M80.5M87.8M80.5M761.8M510.3M573M594.9M653.7M492M138.9M75.1M
Combined Ratio %92.54%92.85%82.4%86.68%85.26%89.35%92.67%88.48%94.59%87.56%87.8%88.46%94.85%88.23%88.12%96.76%87.05%87.19%91.75%90.52%95.58%93.2%102.48%104.61%93.68%91.63%90.95%101.77%89.2%80.69%25.84%
Operating Income992.6M933.5M2.25B1.64B1.75B1.26B964M1.38B627.8M1.4B1.35B1.24B542M1.22B1.25B333.3M1.32B1.29B824M997.2M465.4M709.6M-259.5M-452.4M574.3M753.8M821.2M-165.5M920.2M1.48B3.02B
Operating Margin %7.46%7.15%17.6%13.32%14.74%10.65%7.33%11.52%5.41%12.44%12.2%11.54%5.15%11.77%11.88%3.24%12.95%12.81%8.25%9.48%4.42%6.8%-2.48%-4.61%6.32%8.37%9.05%-1.77%10.8%19.31%74.16%
Operating Income Growth %--58.54%37.27%-6.28%38.82%30.77%-30.25%120.15%-55.28%4.18%8.83%128.47%-55.57%-2.36%274.89%-74.75%2.14%56.83%-17.37%114.27%-34.41%373.45%42.64%-178.77%-23.81%-8.21%596.19%-117.99%-37.94%-50.89%9.39%
EBITDA1.09B1.06B2.37B1.75B1.86B1.38B1.08B1.49B729.2M1.51B1.45B1.34B629.9M1.3B1.33B414.4M1.4B1.37B892.8M1.06B545.9M797.4M-179M309.4M1.08B1.33B1.42B488.2M1.41B1.62B3.09B
EBITDA Margin %8.16%8.09%18.51%14.21%15.67%11.66%8.2%12.44%6.29%13.36%13.12%12.47%5.99%12.58%12.68%4.03%13.69%13.54%8.94%10.11%5.18%7.64%-1.71%3.15%11.94%14.74%15.61%5.23%16.58%21.12%76%
Interest Expense209.9M208.8M201.1M194.8M188.5M185M188.2M177.4M167.3M159.9M166M152.8M167.5M149.4M145.4M143.3M141.8M125.4M156.7M241.9M191.8M208M207.1M187.2M162.4M169.6M181.8M137.8M119.9M84.9M241.3M
Non-Operating Income-156.8M-208.8M-201.1M-194.8M-188.5M-185M-188.2M-177.4M-167.3M-159.9M-166M-152.8M-167.5M-149.4M-145.4M-143.3M-141.8M-125.4M-156.7M-241.9M-191.8M-208M-207.1M-204.4M-162.4M-169.6M-181.8M-137.8M-119.9M1.4B2.78B
Pretax Income992.6M933.5M2.25B1.64B1.75B1.26B964M1.38B627.8M1.4B1.35B1.24B542M1.22B1.25B333.3M1.32B1.29B824M997.2M465.4M709.6M-259.5M-452.4M574.3M753.8M821.2M-165.5M920.2M916.7M341.6M
Pretax Margin %7.46%7.15%17.6%13.32%14.74%10.65%7.33%11.52%5.41%12.44%12.2%11.54%5.15%11.77%11.88%3.24%12.95%12.81%8.25%9.48%4.42%6.8%-2.48%-4.61%6.32%8.37%9.05%-1.77%10.8%11.94%8.39%
Income Tax211.2M195M472.2M356.3M342.8M279.6M171M281.8M104.4M409.8M416.3M371.2M139.9M373M355.1M49.1M441.2M439.7M270.8M324.8M61.8M196M-67.3M-177.9M196.3M216.1M284M17.4M302.8M299.1M103.6M
Effective Tax Rate %21.28%20.89%20.97%21.72%19.59%22.18%17.74%20.39%16.63%29.19%30.89%29.98%25.81%30.57%28.42%14.73%33.43%34.02%32.86%32.57%13.28%27.62%25.93%39.32%34.18%28.67%34.58%-10.51%32.91%32.63%30.33%
Net Income781.4M738.5M1.78B1.28B1.41B981M793M1.1B523.4M994.2M931.4M867.1M402.1M847M894.4M284.2M878.7M852.6M553.2M679.3M411M513.6M-253M-386.4M401.2M541.2M538.9M-182.9M617.4M617.6M238M
Net Margin %5.87%5.66%13.91%10.43%11.85%8.29%6.03%9.17%4.51%8.81%8.43%8.08%3.82%8.17%8.51%2.77%8.62%8.45%5.54%6.46%3.9%4.92%-2.42%-3.94%4.42%6.01%5.94%-1.96%7.25%8.04%5.85%
Net Income Growth %-50.32%-58.49%38.58%-8.77%43.45%23.71%-27.93%110.22%-47.35%6.74%7.42%115.64%-52.53%-5.3%214.71%-67.66%3.06%54.12%-18.56%65.28%-19.98%303%34.52%-196.31%-25.87%0.43%394.64%-129.62%-0.03%159.5%-15.33%
EPS (Diluted)4.754.289.466.506.964.023.895.242.384.373.953.501.573.233.170.942.692.571.621.911.231.64-0.86-1.481.662.212.22-0.772.542.571.61
EPS Growth %-45.82%-54.76%45.54%-6.61%73.13%3.34%-25.76%120.17%-45.54%10.63%12.86%122.93%-51.39%1.89%237.23%-65.06%4.67%58.64%-15.18%55.28%-25%290.7%41.89%-189.16%-24.89%-0.45%388.31%-130.31%-1.17%59.63%-16.15%
EPS (Basic)-4.289.496.537.014.043.895.252.384.393.963.511.573.243.180.942.702.571.621.921.271.74-0.86-1.481.662.242.24-0.772.602.621.63
Diluted Shares Outstanding164.4M172.92M188.07M197.6M202.11M204.85M203.76M209.85M220.1M227.3M236M247.9M256.11M265.9M281.76M303.57M327.22M332.14M341.56M355.78M334.15M313.17M294.19M261.33M243.48M244.89M242.75M237.53M141.24M143.46M147.83M

Key Metrics

Growth RegimeStable
ProfitabilityModerate
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Legacy LTC reserve volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Growth Sustains Moderate Momentum

According to recent financial disclosures, Unum Group achieved a 9.0% revenue growth rate in 2026Q1, suggesting that the company's core disability and supplemental benefit segments are successfully navigating the current labor market environment while maintaining consistent demand for workplace-based insurance products across its primary US operations.

The revenue trajectory appears stable, supported by the company's ability to capture recurring premiums despite broader economic uncertainties. Investors should monitor whether this growth is driven by new policy acquisition or inflationary adjustments to existing benefit levels, as the latter may mask underlying volume stagnation.

Underwriting Profitability Faces Periodic Volatility

As reported in quarterly filings, the combined ratio fluctuated significantly, reaching a low of 72.3% in 2024Q3 before normalizing to 91.0% in 2026Q1, which indicates that while core underwriting remains profitable, the company is susceptible to episodic spikes in claims activity that pressure operating margins.

The variance in the loss ratio suggests that morbidity experience remains the primary variable impacting profitability. The company's ability to maintain a combined ratio consistently below the 100% threshold implies effective risk pricing, though the volatility warrants caution regarding the predictability of future underwriting gains.

Legacy Block Distorts Earnings Profile

Based on the provided income statement data, the 2024Q3 period serves as a clear inflection point where a sharp decline in claims to $95.6 million drove an anomalous quarterly net income of $645.7 million, highlighting the outsized impact of reserve adjustments on the company's reported financial results.

This period underscores the difficulty in assessing core operational performance when legacy liabilities are subject to significant actuarial revaluation. Analysts should treat such quarters as non-recurring events rather than evidence of a structural improvement in the underlying disability insurance business model.

Reserve Adequacy Remains Primary Concern

Financial statements indicate that the loss ratio reached 78.0% in 2025Q3, a notable deviation from the more stable ranges observed in other periods, which may suggest that the company's long-term disability reserves are sensitive to shifting claim duration trends that could challenge future earnings stability.

The potential for post-viral syndromes or other long-term health trends to extend claim durations poses a risk to the current reserve assumptions. Investors should investigate whether the company is adequately accounting for these emerging morbidity risks or if current profitability is being flattered by overly optimistic actuarial modeling.

UNMA — Frequently Asked Questions

Quick answers to the most common questions about buying UNMA stock.

What was Unum Group 6.250% JR NT58's (UNMA) revenue in 2025?

For fiscal year 2025, Unum Group 6.250% JR NT58 (UNMA) reported total revenue of $13.05B. This represents a 220.6% increase compared to $4.07B in 1996.

Is Unum Group 6.250% JR NT58 (UNMA) profitable?

Unum Group 6.250% JR NT58 (UNMA) is profitable, generating $738.5M in net income for the fiscal year ending 2025 with a net profit margin of 5.7%.

What is Unum Group 6.250% JR NT58's operating profit margin?

Unum Group 6.250% JR NT58 (UNMA) reported an operating income of $933.5M, resulting in an operating profit margin of 7.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Unum Group 6.250% JR NT58's gross profit and gross margin?

Unum Group 6.250% JR NT58 (UNMA) generated $4.99B in gross profit for the year, representing a gross profit margin of 38.2%. This demonstrates the company's core pricing power and production efficiency.